PRESS RELEASE published on 02/24/2026 at 15:30, 2 months 10 days ago Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Dupixent de Sanofi et Regeneron approuvé par la FDA aux États-Unis pour traiter la rhinosinusite fongique allergique, offrant un soulagement aux patients de tous âges Traitement Sanofi Dupixent Regeneron Rhinosinusite Fongique Allergique
PRESS RELEASE published on 02/24/2026 at 15:30, 2 months 10 days ago Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease Sanofi Phase 3 Study Dupixent Regeneron Allergic Fungal Rhinosinusitis
BRIEF published on 02/17/2026 at 19:05, 2 months 17 days ago Sanofi publie son Document d'Enregistrement Universel 2025 Rapport Financier SEC Durabilité Sanofi Document D'enregistrement
BRIEF published on 02/17/2026 at 19:05, 2 months 17 days ago Sanofi publishes its 2025 Universal Registration Document Sustainability Financial Report Sanofi Registration Document DRY
PRESS RELEASE published on 02/17/2026 at 19:00, 2 months 17 days ago Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Dépôt du Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel et du « Form 20-F » américain par Sanofi. Consultation en ligne disponible Rapport Financier Annuel Form 20-F Document D’enregistrement Universel Sanofi Consultation En Ligne
BRIEF published on 02/17/2026 at 12:05, 2 months 17 days ago Sanofi and Teva: Promising advance in the treatment of inflammatory bowel diseases Ulcerative Colitis Sanofi Teva Crohn's Disease Duvakitug
BRIEF published on 02/17/2026 at 12:05, 2 months 17 days ago Sanofi et Teva annoncent des résultats positifs de phase 2b pour Duvakitug dans les MICI Maladie De Crohn Rectocolite Hémorragique Étude De Phase 2b Duvakitug Collaboration Sanofi-Teva
BRIEF published on 02/17/2026 at 12:05, 2 months 17 days ago Sanofi et Teva : Avancée prometteuse dans le traitement des maladies inflammatoires intestinales Maladie De Crohn Sanofi Colite Ulcéreuse Teva Duvakitug
BRIEF published on 02/17/2026 at 12:05, 2 months 17 days ago Sanofi and Teva Report Positive Phase 2b Data for Duvakitug in IBD Ulcerative Colitis Crohn’s Disease Phase 2b Study Duvakitug Sanofi-Teva Collaboration
PRESS RELEASE published on 02/17/2026 at 12:00, 2 months 17 days ago Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva montrent une efficacité durable dans la colite ulcéreuse et la maladie de Crohn, renforçant le potentiel du traitement Maladie De Crohn Sanofi Colite Ulcéreuse Teva Duvakitug
Published on 05/07/2026 at 05:40, 2 hours 42 minutes ago New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 6 hours 22 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 8 hours 52 minutes ago Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 9 hours 17 minutes ago Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 9 hours 22 minutes ago Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/07/2026 at 08:05, 17 minutes ago Hyundai Mobis Develops Power Electric Systems Ready to All EV Models
Published on 05/07/2026 at 08:05, 17 minutes ago Nota AI Signs AI Optimization Technology Supply and Strategic Partnership Agreement with Mobilint Accelerating Commercialization of On-Device AI on Domestic NPU Infrastructure
Published on 05/07/2026 at 08:00, 22 minutes ago Financial results Q1 2026 – Strong, profitable growth
Published on 05/07/2026 at 08:00, 22 minutes ago AIXTRON supplied Planetary GaN MOCVD Systems to Renesas for High-Volume Manufacturing Expansion
Published on 05/07/2026 at 08:00, 22 minutes ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
Published on 05/06/2026 at 18:00, 14 hours 22 minutes ago Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 14 hours 22 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 14 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026